A Phase I Open-Label, Dose-escalation Clinical Trial of Tumor Necrosis Factor Alpha and Interleukin-2 Coding Oncolytic Adenovirus TILT-123 in combination with avelumab in injectable solid tumor patients (melanoma and SCCHN) refractory to or progressing after anti-PD(L)1 immunotherapy

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-518088-37-01

Acronym

TILT-T776

Enrollment

Registered

2024-12-04

Start date

2024-12-04

Completion date

Unknown

Last updated

2025-12-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Melanoma, SCCHN

None listed

Sex/Gender

All

Age

18 Years to No maximum

Finland

None listed

Source: EU CTIS · Data processed: Feb 4, 2026